We generated PDX models using multi-region spatial and temporal sampling of tumors from patients with EGFR-mutant NSCLC enrolled in a prospective clinical trial assessing LAT after osimertinib resistance (NCT02759835; Fig. 1A). This evidence concerns the gene EGFR and non-small cell lung carcinoma.